Randomized clinical trial comparing the effect of different homeostatic agents for controlling homeostasis after hepatic resection.

Randomized clinical trial comparing the effect of Surgicel, TachoSil and Glubran 2 in controlling bleeding after liver resection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013031712834N1

Enrollment

Registered

2013-05-01

Start date

2013-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Liver metastasis. Condition 2: Malignant neoplasm of liver and intrahepatic bile ducts. Condition 3: Topical homeostatic agents. Condition 4: Other diseases of liver in need of surgery. Secondary malignant neoplasm of liver and intrahepatic bile duct Malignant neoplasm of liver and intrahepatic bile ducts Topical agent, unspecified Other specified diseases of liver

Interventions

Intervention 1: In Surgicel group, Surgicel (a topical cellulose homeostatic agent) in the size of 10*20 cm will be used to control bleeding. Intervention 2: In TachoSil group, TachoSil (contains hum

Treatment - Drugs

In Surgicel group, Surgicel (a topical cellulose homeostatic agent) in the size of 10*20 cm will be used to control bleeding

In TachoSil group, TachoSil (contains human coagulation factor components: fibrinogen and thrombin) in the size of 4.8*4.8 cm will be used to control bleeding

In Glubran2 group, one Glubran2 glue (N-butyl -2-cyanoacrylate) will bee used to control bleeding.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 18-75 years old; all patients undergoing hepatic resection and have oozing after resection; patients with no coagulation disorders Exclusion criteria: Death during the surgery;hepatic mass to be none resectable; early closure of the surgery; hepatic insufficiency after surgery; coagulopathy after the surgery; patients with need for re-surgery due to bleeding or bile leakage other than resection site; patients with chronic hepatic disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bleeding control. Timepoint: Every 6 hours until 48 hours. Method of measurement: Observation during surgery and evaluation of Hb, INR every 6 hours.	—

Secondary

Measure	Time frame
Complications after oozing control. Timepoint: Days 1, 3, 5,7 after surgery. Method of measurement: Physical examination and paraclinical evaluations.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mir Salim Seayed Sadeghi

Tabriz University of Medical Sciences

seayedsadeghim@tbzmed.ac.ir+98 41 1334 1317

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026